Great Point Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Great Point Partners’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-669,472	Closed	-$17.3M	–	49
2017 Q4	$17.3M	Sell	669,472 -1,336,739	-67%	-$26.9M	2.96%	14
2017 Q3	$29.6M	Buy	2,006,211 +6,211	+0.3%	+$90.1K	5.76%	4
2017 Q2	$27.9M	Sell	2,000,000 -200,000	-9%	-$2.95M	5%	7
2017 Q1	$37.5M	Buy	+2,200,000	New	+$26.4M	7.45%	2

Other funds holding CNCE

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Great Point Partners's CNCE Position: Q1 2018 in Review

Great Point Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2018, closing a stake of 669,472 shares — an estimated $17.3M sold.

Great Point Partners first reported a position in CNCE in Q1 2017 and held it in 4 quarters. The position peaked at $37.5M in Q1 2017. 123 funds tracked by Wall St. Rank hold CNCE as of Q1 2018.

Great Point Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Great Point Partners sold 669,472 Concert Pharmaceuticals, Inc. shares in Q1 2018, an estimated $17.3M.
Great Point Partners first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 4 quarters.
Great Point Partners's Concert Pharmaceuticals, Inc. position peaked at $37.5M in Q1 2017.
123 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2018.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.